Kairos Pharma, Ltd.
KAPA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.49M
Close$
$1.71
249.7% upside
Current Fair Value
249.7% upsideUndervalued by 249.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.49 Million |
|---|---|
| Enterprise Value | $-1,132,993.00 |
| Earnings per Share | $-2.1 |
| Beta | 1.44 |
| Outstanding Shares | 3,060,068 |
Return
| Return on Equity | -138.51% |
|---|---|
| Return on Assets | -130.27% |
| Return on Invested Capital | -138.51% |
Valuation & Multiples
| P/E Ratio | -0.25 |
|---|---|
| PEG | 10.54 |
| Price to Sales | - |
| Price to Book Ratio | 0.49 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.17 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.63
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.63
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.52%▲ 1.66% |
|---|---|
| Total Invested | $371,096▲ 8.66% |
| Investors Holding | 14▲ 3.00% |
About Kairos Pharma, Ltd.
4 employees
CEO: John S. Yu
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineer...